19 related articles for article (PubMed ID: 9725749)
1. Prediction of consensus binding mode geometries for related chemical series of positive allosteric modulators of adenosine and muscarinic acetylcholine receptors.
Sakkal LA; Rajkowski KZ; Armen RS
J Comput Chem; 2017 Jun; 38(15):1209-1228. PubMed ID: 28130813
[TBL] [Abstract][Full Text] [Related]
2. DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats.
Kato T; Matsumoto Y; Yamamoto M; Matsumoto K; Baba S; Nakamichi K; Matsuda H; Nishimuta H; Yabuuchi K
Pharmacol Res Perspect; 2015 Jun; 3(3):e00142. PubMed ID: 26171224
[TBL] [Abstract][Full Text] [Related]
3. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM
Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of phospholipase C-β1 in the medial prefrontal cortex of male mice impairs working memory among multiple schizophrenia endophenotypes.
Kim SW; Seo M; Kim DS; Kang M; Kim YS; Koh HY; Shin HS
J Psychiatry Neurosci; 2015 Mar; 40(2):78-88. PubMed ID: 25268789
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
6. Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area.
Hodges H; Peters S; Gray JA; Hunter AJ
Behav Brain Res; 1999 Feb; 99(1):81-92. PubMed ID: 10512575
[TBL] [Abstract][Full Text] [Related]
7. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.
Harries MH; Samson NA; Cilia J; Hunter AJ
Br J Pharmacol; 1998 May; 124(2):409-15. PubMed ID: 9641560
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
Watson JM; Hunter AJ; Brown AM; Middlemiss DN
Eur J Pharmacol; 1999 Apr; 370(1):69-77. PubMed ID: 10323282
[TBL] [Abstract][Full Text] [Related]
9. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
10. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Stengel PW; Cohen ML
J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
[TBL] [Abstract][Full Text] [Related]
11. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.
Hatcher JP; Loudon JM; Hagan JJ; Clark MS
Psychopharmacology (Berl); 1998 Aug; 138(3-4):275-82. PubMed ID: 9725749
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
